Reminder for Medpace Shareholder Class Action
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: PRnewswire
- Class Action Notice: Rosen Law Firm reminds investors who purchased Medpace Holdings, Inc. (NASDAQ:MEDP) common stock between April 22, 2025, and February 9, 2026, to apply as lead plaintiffs by June 8, 2026, to participate in the class action and potentially receive compensation.
- Fee Arrangement: Investors joining the class action will not incur any upfront costs, as the law firm operates on a contingency fee basis, thereby reducing the financial burden on investors.
- Lawsuit Background: The lawsuit alleges that Medpace made false and misleading statements regarding its true backlog cancellation rates during the class period, leading investors to have overly optimistic growth expectations that ultimately resulted in financial losses.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first in 2017 for the number of securities class action settlements, showcasing its expertise and success in this field.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MEDP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MEDP
Wall Street analysts forecast MEDP stock price to rise
7 Analyst Rating
1 Buy
4 Hold
2 Sell
Hold
Current: 450.815
Low
462.00
Averages
569.17
High
660.00
Current: 450.815
Low
462.00
Averages
569.17
High
660.00
About MEDP
Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Medpace's Earnings Outlook Shows Optimism Ahead of Report
- Stock Performance: Medpace (MEDP) closed at $445.59, down 1.3%, lagging behind the S&P 500's daily gain of 0.13%, indicating market caution regarding its short-term performance.
- Monthly Growth: Despite the daily decline, Medpace's stock rose 8.26% over the past month, outperforming the Medical sector's 1.01% gain, suggesting strong ongoing demand in the clinical development services market.
- Earnings Forecast: The upcoming earnings report is expected to show an EPS of $4.08, reflecting a 31.61% year-over-year increase, with revenue projected at $678.51 million, a 12.47% increase, providing positive growth signals for investors.
- Valuation Analysis: Medpace holds a forward P/E ratio of 26.5, significantly above the industry average of 15.1, with a PEG ratio of 2.29, indicating high market expectations for future earnings growth, while currently rated Zacks Rank #3 (Hold), the industry ranks in the top 40%, reflecting overall industry health.
See More
Class Action Lawsuit Filed Against Medpace Holdings, Inc.
- Lawsuit Background: Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Medpace Holdings, Inc. on behalf of investors who purchased shares between April 22, 2025, and February 9, 2026, alleging that the company made false and misleading statements that artificially inflated its stock price during this period.
- Investor Losses: The complaint indicates that Medpace's misrepresentations became evident through poor market performance, leading to significant losses for investors once the truth was revealed, highlighting serious deficiencies in the company's disclosure practices.
- Legal Process: Investors are required to apply by June 5, 2026, to be appointed as lead plaintiffs in the lawsuit, underscoring the urgency of the case and the need for protection of shareholder rights, reflecting the legal system's commitment to investor interests.
- Law Firm Overview: Bragar Eagel & Squire, P.C. is a nationally recognized law firm specializing in securities, derivative, and commercial litigation, demonstrating its expertise and broad influence in advocating for investor rights.
See More
Reminder for Medpace Shareholder Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Medpace Holdings, Inc. (NASDAQ:MEDP) common stock between April 22, 2025, and February 9, 2026, to apply as lead plaintiffs by June 8, 2026, to participate in the class action and potentially receive compensation.
- Fee Arrangement: Investors joining the class action will not incur any upfront costs, as the law firm operates on a contingency fee basis, thereby reducing the financial burden on investors.
- Lawsuit Background: The lawsuit alleges that Medpace made false and misleading statements regarding its true backlog cancellation rates during the class period, leading investors to have overly optimistic growth expectations that ultimately resulted in financial losses.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first in 2017 for the number of securities class action settlements, showcasing its expertise and success in this field.
See More
Medpace Faces Class Action Lawsuit Amid Stock Plunge
- Class Action Initiated: Pomerantz LLP has announced a class action lawsuit against Medpace Holdings, alleging securities fraud and other unlawful business practices by the company and certain officers, with investors needing to apply as Lead Plaintiff by June 8, 2026, indicating potential legal risks that could impact the company's reputation and shareholder confidence.
- Disappointing Earnings Report: On February 9, 2026, Medpace released its fourth-quarter 2025 earnings, revealing a book-to-bill ratio of only 1.04, significantly below the company's guidance, reflecting weak business growth that may heighten investor concerns about future performance.
- Stock Price Plunge: Following the earnings report, Medpace's stock price fell by $84.30, or 15.9%, closing at $446.05 on February 10, 2026, demonstrating the market's strong reaction to the company's financial health, which could affect its future financing capabilities.
- Legal Background: Pomerantz LLP is a prominent law firm specializing in securities class litigation, founded over 85 years ago to advocate for victims of securities fraud, and this lawsuit may attract further investor attention, potentially impacting Medpace's market performance.
See More
Medpace Holdings Faces Class Action Lawsuit Reminder
- Class Action Notification: The Schall Law Firm reminds investors of a class action lawsuit against Medpace Holdings (NASDAQ:MEDP) for violations of securities laws during the period from April 22, 2025, to February 9, 2026, with a deadline for participation set for June 5, 2026.
- False Statement Allegations: The complaint alleges that Medpace made false and misleading statements that artificially inflated its stock price, leading to significant investor losses when the truth was revealed, highlighting serious issues with the company's financial transparency.
- Legal Consultation Opportunity: The Schall Law Firm offers free legal consultations to affected investors, encouraging them to reach out to protect their rights, demonstrating the firm's commitment to safeguarding shareholder interests.
- Lawsuit Status: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs, underscoring the importance of participating in the lawsuit for potential future compensation.
See More
Medpace Executives Face Securities Class Action
- Significant Stock Drop: Medpace Holdings Inc. experienced a stock decline of $84.30 per share, over 15.9%, after revealing a Q4 2025 book-to-bill ratio of 1.04, which was below the expected 1.15, severely impacting investor confidence.
- Executive Accountability: Three senior executives, including CEO Troendle and CFO Brady, are accused of providing misleading information in SEC filings, potentially facing personal liability under Section 20(a) of the Securities Exchange Act of 1934, which could harm the company's reputation and future financing capabilities.
- Deadline for Lawsuit Participation: Investors must apply by June 8, 2026, to be considered for lead plaintiff status, which may prompt more investors to take action and increase participation in the lawsuit.
- Legal Consultation Opportunity: Levi & Korsinsky LLP offers free evaluations, encouraging affected investors to gather trading records to participate in claims, which may attract more investor attention and involvement in the lawsuit.
See More
Medpace's Earnings Outlook Shows Optimism Ahead of Report
- Stock Performance: Medpace (MEDP) closed at $445.59, down 1.3%, lagging behind the S&P 500's daily gain of 0.13%, indicating market caution regarding its short-term performance.
- Monthly Growth: Despite the daily decline, Medpace's stock rose 8.26% over the past month, outperforming the Medical sector's 1.01% gain, suggesting strong ongoing demand in the clinical development services market.
- Earnings Forecast: The upcoming earnings report is expected to show an EPS of $4.08, reflecting a 31.61% year-over-year increase, with revenue projected at $678.51 million, a 12.47% increase, providing positive growth signals for investors.
- Valuation Analysis: Medpace holds a forward P/E ratio of 26.5, significantly above the industry average of 15.1, with a PEG ratio of 2.29, indicating high market expectations for future earnings growth, while currently rated Zacks Rank #3 (Hold), the industry ranks in the top 40%, reflecting overall industry health.
See More
Class Action Lawsuit Filed Against Medpace Holdings, Inc.
- Lawsuit Background: Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Medpace Holdings, Inc. on behalf of investors who purchased shares between April 22, 2025, and February 9, 2026, alleging that the company made false and misleading statements that artificially inflated its stock price during this period.
- Investor Losses: The complaint indicates that Medpace's misrepresentations became evident through poor market performance, leading to significant losses for investors once the truth was revealed, highlighting serious deficiencies in the company's disclosure practices.
- Legal Process: Investors are required to apply by June 5, 2026, to be appointed as lead plaintiffs in the lawsuit, underscoring the urgency of the case and the need for protection of shareholder rights, reflecting the legal system's commitment to investor interests.
- Law Firm Overview: Bragar Eagel & Squire, P.C. is a nationally recognized law firm specializing in securities, derivative, and commercial litigation, demonstrating its expertise and broad influence in advocating for investor rights.
See More
Reminder for Medpace Shareholder Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Medpace Holdings, Inc. (NASDAQ:MEDP) common stock between April 22, 2025, and February 9, 2026, to apply as lead plaintiffs by June 8, 2026, to participate in the class action and potentially receive compensation.
- Fee Arrangement: Investors joining the class action will not incur any upfront costs, as the law firm operates on a contingency fee basis, thereby reducing the financial burden on investors.
- Lawsuit Background: The lawsuit alleges that Medpace made false and misleading statements regarding its true backlog cancellation rates during the class period, leading investors to have overly optimistic growth expectations that ultimately resulted in financial losses.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first in 2017 for the number of securities class action settlements, showcasing its expertise and success in this field.
See More
Medpace Faces Class Action Lawsuit Amid Stock Plunge
- Class Action Initiated: Pomerantz LLP has announced a class action lawsuit against Medpace Holdings, alleging securities fraud and other unlawful business practices by the company and certain officers, with investors needing to apply as Lead Plaintiff by June 8, 2026, indicating potential legal risks that could impact the company's reputation and shareholder confidence.
- Disappointing Earnings Report: On February 9, 2026, Medpace released its fourth-quarter 2025 earnings, revealing a book-to-bill ratio of only 1.04, significantly below the company's guidance, reflecting weak business growth that may heighten investor concerns about future performance.
- Stock Price Plunge: Following the earnings report, Medpace's stock price fell by $84.30, or 15.9%, closing at $446.05 on February 10, 2026, demonstrating the market's strong reaction to the company's financial health, which could affect its future financing capabilities.
- Legal Background: Pomerantz LLP is a prominent law firm specializing in securities class litigation, founded over 85 years ago to advocate for victims of securities fraud, and this lawsuit may attract further investor attention, potentially impacting Medpace's market performance.
See More
Medpace Holdings Faces Class Action Lawsuit Reminder
- Class Action Notification: The Schall Law Firm reminds investors of a class action lawsuit against Medpace Holdings (NASDAQ:MEDP) for violations of securities laws during the period from April 22, 2025, to February 9, 2026, with a deadline for participation set for June 5, 2026.
- False Statement Allegations: The complaint alleges that Medpace made false and misleading statements that artificially inflated its stock price, leading to significant investor losses when the truth was revealed, highlighting serious issues with the company's financial transparency.
- Legal Consultation Opportunity: The Schall Law Firm offers free legal consultations to affected investors, encouraging them to reach out to protect their rights, demonstrating the firm's commitment to safeguarding shareholder interests.
- Lawsuit Status: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs, underscoring the importance of participating in the lawsuit for potential future compensation.
See More
Medpace Executives Face Securities Class Action
- Significant Stock Drop: Medpace Holdings Inc. experienced a stock decline of $84.30 per share, over 15.9%, after revealing a Q4 2025 book-to-bill ratio of 1.04, which was below the expected 1.15, severely impacting investor confidence.
- Executive Accountability: Three senior executives, including CEO Troendle and CFO Brady, are accused of providing misleading information in SEC filings, potentially facing personal liability under Section 20(a) of the Securities Exchange Act of 1934, which could harm the company's reputation and future financing capabilities.
- Deadline for Lawsuit Participation: Investors must apply by June 8, 2026, to be considered for lead plaintiff status, which may prompt more investors to take action and increase participation in the lawsuit.
- Legal Consultation Opportunity: Levi & Korsinsky LLP offers free evaluations, encouraging affected investors to gather trading records to participate in claims, which may attract more investor attention and involvement in the lawsuit.
See More
